Novartis Wins FDA Nod for First Biosimilar Version of Biogen’s MS Blockbuster Tysabri

The FDA endorsed Novartis’ Tyruko as the first US biosimilar to treat multiple sclerosis (MS). The new treatment covers all of Tysabri’s indications for relapsing MS, in addition to Crohn’s disease.